SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to a Cornell University study highlighting its APU's comparable GPU performance with significantly lower energy consumption, sparking discussions about its potential to disrupt the AI inference market and compete with major players like NVDA. The community is actively debating the implications of this technology, potential market share, and possible acquisition scenarios. Additionally, some traders are closely monitoring potential short squeezes.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to recent positive preliminary earnings and raised revenue guidance, sparking discussions about a potential short squeeze given the high short interest. The community is also focused on the company's strategic investment in TLPH and potential acquisitions, with some speculating about future price targets. Bullish sentiment is growing as the company expands its market presence and portfolio.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending due to a widespread AWS outage impacting numerous websites and applications, sparking community discussion about the company's infrastructure and potential lawsuits. Despite the service disruption, the stock price saw an increase, fueling debates about market dynamics and AWS's overall importance. Some investors believe the outage highlights the world's dependence on Amazon, while others anticipate a negative impact on earnings and a potential shift to alternative cloud providers.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending as traders anticipate the Phase 3 AFFIRM-1 trial results for BNC-210 in social anxiety disorder (SAD), with some expecting data imminently. The community is actively discussing the potential for a significant price surge similar to SPRB if the results are positive, given NEUP's tight float and low market cap. Some are pointing to a Merck partnership and extended cash runway as additional bullish signals.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as traders react to news of the company exploring rare earth mineral production, overshadowing a revenue miss. The community is focused on the potential shift from steel to strategic minerals, and the implications for the company's future. Some traders express caution, citing debt and past performance, while others see the rare earth pivot and potential government support as bullish signals.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune (REPL) is trending due to resubmission news regarding their Biologics License Application for RP1, a melanoma treatment, with the FDA setting a PDUFA date for April 2026. The community is actively debating the significance of the resubmission versus full approval and the potential for a price target of $18. Some traders are also discussing the possibility of a near-term offering, while others believe the stock has strong support.

Storing value in digital art. Project launched by famous Korean artist with 144k instagram followers and millions of interactions. Created a token behind his digital art character ‘CUTIE’. The crypto community on X decided to support the artist by sharing his work to wider audiences. The artist is affiliated with some renowned names that have established and successful projects in the crypto space such as the artist behind $nub the silly nub cat.

Cute Style

CUTIE is trending as traders discuss its chart appearance and potential entry points. Community members are sharing links to charts and expressing bullish sentiment, while some traders suggest caution despite following signals from experienced investors. The conversation highlights interest in CUTIE's momentum and recent price action.

Zions Bancorporation NA is a bank holding company, which engages in the provision of full banking and related services. It operates through the following segments: Zions Bank, Amegy Bank, California Bank & Trust, National Bank of Arizona, Nevada State Bank, Vectra Bank Colorado, and The Commerce Bank of Washington. The company was founded on February 17, 1961, and is headquartered in Salt Lake City, UT.

Zions Bancorporation N.A

Zions Bancorporation is trending as investors react to recent earnings and news of a charge-off related to bad loans, sparking concerns about credit risks and loan quality. The community is debating the significance of the charge-off, with some seeing it as an isolated incident while others express doubts about the company's complete financial picture. Despite mixed sentiment, some analysts suggest the selloff was overdone, and the stock is experiencing notable price swings.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending following its listing on Robinhood, a move long awaited by the community. Community members are speculating on the potential price impact, drawing comparisons to past meme coin surges and highlighting Floki's smaller market cap compared to DOGE and SHIB. The listing provides increased accessibility and exposure for the token.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

ATMV is trending due to discussions around its low float and acquisition news, with some traders reporting substantial gains. Community members are pointing to the stock's volatile price action and previous highs, while also questioning its legitimacy as a shell company. The stock has been identified as a top gainer across multiple timeframes, contributing to increased attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq) versus...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX (cabozantinib) versus placebo in patients with previously...

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Do Options Traders Know Something About Exelixis Stock We Don't?

Investors need to pay close attention to EXEL stock based on the movements in the options market lately.

Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.

Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?

EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$34.54
Prev Close	$39.25
Open	$35.55
Dividend Yield	0.00%
50-Day Moving Average	$38.83
Beta	0.50
Avg. Volume	2.57M
PE Ratio	18.82

52-Week High	$49.62
52-Week Low	$27.86
Market Capitalization	$10.57B
EPS (Annual)	$1.76
Price to Book	5.21
Revenue Per Employee	$1.89M
Enterprise Value/EBITDA	N/A

EXEL
Exelixis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EXEL News

EXELExelixis Inc